Sobi’s Gamifant receives final rejection from CHMP for primary HLH – PMLiVE

The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has given Sobis Gamifant a final negative opinion after re-examining its initial decision.

Sobi requested that the CHMP re-examine the application for Gamifant (emapalumab) as a treatment for of primary haemophagocytic lymphohistiocytosis (HLH) after the Committee initially rejected the drug in July.

Primary HLH is a genetic disease characterised by widespread destruction of blood cells, extremely high iron levels in the blood, coagulation problems and excessive growth of organs.

The condition can be passed on genetically by parents who are carriers of the disease, or can occur as a spontaneous mutation. It results in an over-expression of IFN gamma that causes an auto-immune-like syndrome.

Patients with primary HLH are limited to haematopoietic stem cell transplantation (HSCT), a procedure which requires individuals to undergo intense treatment first in order for it to be successful.

In its original decision, the CHMP ruled that the results of the study used to support Sobis application for Gamifant were not convincing enough to conclude that the drug is effective in the treatment of primary HLH.

In addition, the CHMP said that the study only involved a small number of patients, who were also receiving other medicines used to treat HLH. This, the Committee said, made it difficult to determine if the responses seen in some patients were due to Gamifant treatment.

The CHMP also called into question the data concerning the safety of Gamifant, saying in a statement that the design of the study made it difficult to collect data on the drugs side effects.

After re-examining the available data, as well as additional advice from a group of experts, the CHMP determined that although Sobi had addressed concerns over Gamifants safety profile, the other concerns still remained.

"This recommendation by the CHMP is disappointing given the significant unmet medical need which exists for patients with pHLH who have no approved therapies in Europe, said Ravi Rao, head of R&D and chief medical officer at Sobi

During the re-examination we worked extensively with physicians and patients and were able to resolve some but not all of the concerns raised by EMA.

"We are confident about the clinical profile of emapalumab and our focus is now on increasing access for patients in other regions and developing new indications for this medicine, he added.

Sobi, based in Stockholm, Sweden, acquired the global marketing rights to Gamifant from Novimmune in July 2018, and in June 2019 the company spent $518m to acquire the outstanding intellectual property and patents for the drug.

Gamifant was approved by the US Food and Drug Administration (FDA) for the treatment of primary HLH in November 2018. In the US, over 100 primary HLH patients have been treated with Gamifant, with the benefit/risk profile continuing to prove favourable according to Sobi.

Read more:
Sobi's Gamifant receives final rejection from CHMP for primary HLH - PMLiVE

Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic Cancers – Targeted Oncology

There has been a surge in treatment advancements for multiple myeloma that have improved outcomes for patients in the front- and later-line disease settings, creating an eager need to keep abreast of these latest systemic therapy innovations. In an interview with Targeted Therapies in Oncology, Sagar Lonial, MD, program cochair for the upcoming 24th Annual International Congress on Hematologic Malignancies. hosted by Physicians Education Resource., LLC (PER.), detailed breakthroughs in the care of patients with multiple myeloma as well as other hematologic cancers, and offered a preview of what attendees might expect to hear at the meeting.

Particularly in the era of COVID-19 [coronavirus disease 2019] where so much information is continuing to come out but the live meeting opportunities are limited, [this meeting] provides an opportunity to hear from leading experts in their fields [giving] you the moment to moment changes that are occurring, said Lonial, who is also a professor and the chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia. These changes are occurring so fast, its hard for the [community oncologist] to keep up.

Anti-BCMA Agents and Other Advances in Multiple Myeloma

Lonial detailed the FDAs August 2020 approval of the B-cell maturation antigen (BCMA) antibody-drug conjugate belantamab mafodotin-blmf (Blenrep; Bela-maf) for the treatment of patients with relapsed/refractory disease following at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.1 This marks the first time a systemic therapy agent aimed at inhibiting BCMA received approval in the United States.

We have periods of time where a lot happens. Were seeing BCMA-targeted therapies really come to the forefront, Lonial said. Right now, [there are] 3 different ways to target BCMA. You can use the antibody-drug conjugate bela-maf, you can use a bispecific T-cell engager, or you can use a CAR [chimeric antigen receptor] T-cell therapy.

One of the advantages of targeting BCMA is that it is expressed exclusively on plasma cells, leading to fewer off-target affects, Lonial said. Additionally, BCMA activation has been shown to promote drug resistance,2 so inhibiting it may provide the dual benefit of suppressing tumor growth as well as overcoming drug resistance.

Regarding bispecific T-cell engager (BiTE) therapies, Lonial said clinicians may be familiar with this approach by looking at an established agent for the treatment of acute lymphoblastic leukemia (ALL), blinatumomab (Blincyto). Here, the bispecific CD19-directed T-cell engager binds to CD19 expressed on tumor cells and CD3 expressed on T cells,3 bringing them in close proximity with one another. I was skeptical that this approach would work in myeloma because I thought that T cells would be exhausted, and I wasnt sure youd be able to get them to work. But certainly, at higher doses, it appears that youre getting response [rates above] 65% to 70%.

Two notable BiTEs in clinical development that are aiming at BCMA for the treatment of multiple myeloma include teclistamab (JNJ-7957) and AMG 420, which have both been explored in phase 1 clinical trials (NCT03145181 and NCT02514239, respectively) with results presented at recent medical meetings.

In CAR T-cell therapy, a modality that Lonial said clinicians are familiar with due to recent successes in ALL and large B-cell lymphoma, there are multiple agents in development that target BCMA for the treatment of multiple myeloma. One of the advantages that has come to light over the CD19-directed agents is the lower rates of cytokine release syndrome and neurologic toxicity which account for the most troublesome adverse events of CAR T-cell therapy administration that lead to hospitalization. We dont know if thats a function of BCMA or of myeloma, Lonial said.

Of all BCMA-targeted CAR T-cell therapies, the most advanced in terms of FDA clearance is idecabtagene vicleucel (ide-cel; BB2121), which just earned priority review in September 2020. The Prescription Drug User Fee Act action date has been set as March 27, 2021.4

Other advances in multiple myeloma that Lonial mentioned included the development of the novel cereblon E3 ligase modulator (CELMoD) iberdomide, which has demonstrated response rates of up to 30% in patients with heavily pretreated multiple myeloma when used in conjunction with dexamethasone.5 Additionally, Lonial noted that the use of minimal residual disease (MRD) status as a patient selection tool will become more prominent as more agents are approved across settings.

If somebodys MRD positive, is that where you treat with a BCMA-directed therapy early to try and eliminate that? Those, I think, are really exciting questions were going to be able to answer.

Trends in Cellular Therapy and Other Topics

Lonial said that cellular therapy for the treatment of hematologic diseases by way of allogeneic stem cell transplants, in his view, represented the first time immunotherapy was used for the treatment of any malignancy. Moving into the modern treatment era, investigators are striving to refine these approaches and incorporate new modalities, such as CAR T-cell therapy, for the treatment of patients with hematologic cancers.

Another focus of the meeting will include looking at precision medicine techniques of the solid tumor world and applying those principles to cancers of the blood.

Using genetics and genomics to identify lymphoma subsets is getting us into both an immune era and a precision medicine era, Lonial said. The challenge for us in hematologic malignancies is marrying the 2 concepts together. How do you take both precision medicine and immune therapy and make it one treatment approach for a patient?

Lonial said the CAR T-cell therapy workshop which will be moderated by fellow meeting cochair Andre H. Goy, MD, who is physician in chief of Hackensack Meridian Health Oncology Care Transformation Service, chairman & chief Physician Officer of the John Theurer Cancer Center, Lydia Pfund Chair for lymphoma Academic Academic Chairman Oncology of Hackensack Meridian School of Medicine at Seton Hall University, and professor of medicine at Georgetown Universitymay be especially helpful for all clinicians hoping to learn more about this treatment modality, regardless of whether or not their centers are approved to administer it.

Knowing when to refer from the community [setting to an academic institution] for a CAR T-cell [administration] and what that can offer patients is critically important, he said. The advantage of CAR [T-cell therapy] from my perspective is it is a one-and-done therapy. And if that one-and-done really is done, then its a true victory. We dont want to limit [this only] to people who are seen in academic centers.

Finally, meeting cochair Jorge E. Cortes, MD, the director of Georgia Cancer Center and an Eminent Scholar of the Georgia Research Alliance at Augusta University in Georgia, will moderate sessions addressing the treatment of indolent non-Hodgkin lymphoma and myelodysplastic syndromes, among others.

Lonial concluded by describing what he hopes will be a broad overview for attendees who treat patients in the community and academic settings alike. You get experts in [the treatment of hematologic cancers]which I think is prone for rapid change, expansion, and discoveryto hear in one setting whats newest in lymphoma, whats newest in leukemia, whats newest in myeloma, and whats newest in CAR T-cell therapy. That opportunity is very important, and it provides people with a case-based learning approach.

References:

1. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. FDA. Updated August 6, 2020. Accessed October 27, 2020. https://bit.ly/37M2UDd

2. Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225-3236. doi:10.1182/ blood-2016-01-691162

3. Blincyto. Prescribing information. Amgen; 2020. Accessed October 27, 2020. https://bit.ly/2TsOL5d

4. US Food and Drug Administration (FDA) accepts for priority review Bristol Bristol Myers Squibb and bluebird bio application for anti-BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel, bb2121). News release. Bristol Myers Squibb. September 22, 2020. Accessed October 27, 2020. https://bit.ly/3kDhakH

5. Lonial S, Van de Donk N, Popat R, et al. A phase 1b/2a study of the CELMoD iberdomide (CC-220) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(suppl 10):E52-E53. doi:10.1016/j.clml.2019.09.080

See the rest here:
Meeting Agenda Focuses on Increased Applications of Cellular Therapies in Hematologic Cancers - Targeted Oncology

Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 – re:Jerusalem

Big Market Research, one of the worlds prominent market research firms has released a new report on GlobalAnimal Stem Cell Therapy Market, The report expertise includes assessing new opportunities & sizing, identifying and evaluating complex global value chains (including key drivers, restraints and winning strategies). The report will help the vendor to strategize its positioning in the Animal Stem Cell Therapy Market projects around the globe. The detailed competitor profiling helped identify and understand the key strategies and growth drivers of its competitors. The report includes detailed profile of key competitors, pre/post launch surveys, go-to-market research, supplier selection surveys, industry demand/pain point surveys, pricing analysis, product testing, effectiveness studies, and product positioning studies.

The Animal Stem Cell Therapy Market research report includes:

The Animal Stem Cell Therapy Market report explore:

The Animal Stem Cell Therapy Market includes identification of important potential market demand, expected sale of these devices in the next 5 years, various price and demand sensitive scenarios were built to ascertain on the profitability of investing, customer analysis, and future price analysis.

Ask pdf sample copy of this premium research on Animal Stem Cell Therapy with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4083483?utm_source=PRL&utm_medium=MWA

The Animal Stem Cell Therapy Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Several existing Animal Stem Cell Therapy Industry manufacturers, new start-ups as well as research organizations and universities are constantly coming up with innovative ideas. The Animal Stem Cell Therapy Market is expected to grow exponentially over the next five years with the emergence of new applications and cost competitive products.

Market players have been discussed and profiles of leading players including Top Key Companies: Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Animal Stem Cell Therapy Market By Product Type 2019-2025: Dogs Horses Others

Based on type, the global market is segmented into the following sub-markets with annual revenue for 2015-2025 (historical and forecast) included in each section.

Animal Stem Cell Therapy Market By Application 2019-2025: Veterinary Hospitals Research Organizations

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2019-2025 (historical and forecast) included in each section.

Talk to our Analyst / Ask for a discount on Animal Stem Cell Therapy:https://www.bigmarketresearch.com/request-for-discount/4083483?utm_source=PRL&utm_medium=MWA

The comprehensive competitive landscape section of the report contains detailed analysis of the trends in mergers and acquisitions, agreements and partnerships, new product launches and so on in the Animal Stem Cell Therapy Market. This information will be very useful for existing players as well as new entrants in any market.

Geographically,Animal Stem Cell TherapyMarket is further analyzed into regions and country level analysis:North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Animal Stem Cell Therapy market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Top Trending Reports:

Read More:https://www.bigmarketresearch.com/report/3767216/global-x-ray-security-scanner-sale-insights-market?utm_source=PRL&utm_medium=MWA

About Us:

Big Market Researchhas a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us: Mr. Abhishek Paliwal 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States Direct:+1-971-202-1575 Toll Free:+1-800-910-6452 E-mail:help@bigmarketresearch.com

Visit link:
Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 - re:Jerusalem

Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis – TMR Research Blog

Rheumatoid arthritis refers to an inflammatory disease of the supportive tissues of the body and the condition generally affects fingers and toes of human beings. This inflammation is caused by an abnormal response of the body to the normal functioning tissues. This leads to acute pain and malformed joints. Novel cells that are produced by regenerative centers of the body are called stem cells. These cells can be changed into any other type of cell in the body with just the right kind of stimulant. The growth of the global rheumatoid arthritis stem cell therapy market is likely to observe growth in its ability to demonstrate profound healing activity. It also helps in checking the arthritic condition. In addition to that, this therapy is capable of regenerating and reversing joint tissue in many cases, which is likely to pave way for rapid growth of the global rheumatoid arthritis stem cell therapy market in the years to come.

Get SampleCopy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Ability to Diminish Pain and Inflammation to Bolster Demand in the Market

In present times, human umbilical cord tissue (allogeneic mesenchymal stem cells), fat-derived or adipose stem cells, and bone marrow transplant are utilized for the purpose of the rheumatoid arthritis stem cell therapy. As the condition becomes worse, the body starts autoimmune response and keeps on attacking the cells of the body. The global rheumatoid arthritis stem cell therapy market is estimated to gather momentum from its growing importance and popularity in specialty clinics, ambulatory surgical centers, and hospitals. This therapy comes with the excellent healing capabilities that can treat the entire system causing inflammation and joint pain.

Extensive growth opportunities of the global rheumatoid arthritis stem cell therapy market are likely to be influenced by the multiple benefits offered by this therapy. However, this therapy comes with its own share of disadvantages as well and is not an infallible method for healing arthritis. All though, this therapy is capable of assisting in the stabilization of the body immune system and diminish inflammation.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

Like Loading...

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business. View all posts by Rohit Bhisey

More:
Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis - TMR Research Blog

The Canine Stem Cell Therapy Market To Move Away From Insipidness, Reach US$ 218.2 Mn – PRnews Leader

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte Persistence Market Research Address 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Website https://www.persistencemarketresearch.com

View post:
The Canine Stem Cell Therapy Market To Move Away From Insipidness, Reach US$ 218.2 Mn - PRnews Leader

Stem Cell Therapy Market Growth Analysis 2020 By Industry Top Manufacturers, Business Opportunities, Industry Growth, Size, Gross Margin, Regional…

Global Stem Cell Therapy Market Overview:

Comprehensive Stem Cell Therapy Research has recently been added by Adroit Market Research to its extensive database. In addition, the Stem Cell Therapy Market report has been aggregated by collecting informative data on various dynamics such as market factors, constraints and opportunities. In addition, this groundbreaking report uses SWOT, PESTLE and Porters Five Forces analysis to gain a deeper understanding of the Stem Cell Therapy market. In addition, the Stem Cell Therapy Market report offers an in-depth analysis of the latest industry developments and market trends affecting market growth. It is also a repository of statistical market research and market assessments for Stem Cell Therapys on a global and regional scale. The study examines the impact of various factors and constraints on the growth opportunities of the Stem Cell Therapy market over the forecast period.

Request Sample Copy of this Report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=bh

Global Stem Cell Therapy Market: Competitive Landscape

To gain a head start in a new market, every business must understand the competitive landscape and the ground rules that keep a particular market afloat. The Global Stem Cell Therapy Market Report reveals the secret ingredients competitors are using to meet the needs of their target audience. To specifically understand the need to balance invested capital with profit, organizations should use certain indicators. These indicators will not only help indicate growth, but also warn of impending threats in the near future. The right business plan and approach can guarantee a smooth path forward for every organization.

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report at @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=bh

If firms believe they are offering their potential clients a memorable experience, the Global Stem Cell Therapy Market report will be very helpful. Facts and figures are included in this investigation report to highlight the companys strengths and weaknesses. New technologies are being introduced daily and many new entrants have started their businesses in the market. So, to understand their approach to the market, there is a dedicated section in the Global Stem Cell Therapy Market report. From the financial to the legal aspect, the market report covers all the main points needed to study the market and implement a business plan. Not only that, the competitors added to the report can be changed according to the needs and expectations of the client. In addition, the Global Stem Cell Therapy Market report provides companies with an overview of actions that can propel businesses to emerald heights, both in terms of sales and customer acquisition, over the projected time frame (2020-2025).

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Scope of the Report:

This report provides detailed information on the Stem Cell Therapy market under close scrutiny. Research offers a look at the elements that can hinder business development. Since statistical research also refines the plan for advertising a new product, organizations have time to study the market and take appropriate action. In addition, organizations gain insight into external variables that cannot be controlled. From now on, market research helps measure elements and helps associations to clearly regulate their contribution to the business. Our group of passionate professionals analyzed the social, political and monetary components that affect the Stem Cell Therapy market. In this way, associations can adapt their organizations according to the latest models in order to benefit and create a new customer base.

Regional outlook:

The Stem Cell Therapy market has been studied in various regions of the world such as North America, Latin America, the Middle East, Asia Pacific, Africa and Europe, based on different perspectives such as type, application, market size, etc. North America tops the Market in Stem Cell Therapy Market for the Forecast Period. In addition, the Asia Pacific region is seeing impressive growth in the Stem Cell Therapy market.

Reasons to purchase this report:

It provides market dynamics scenario along with growth opportunities in the forecast period. It determines upcoming opportunities, threats and obstacles that can have an effect on the industry. This report will help in making accurate and time bound business plans keeping in mind the economic shift. To interpret the market competitive advantages of the industry as well as internal competitors. To enhance the creation long term business plans. Regional and country level analysis. Segment wise market value and volume. SWOT, PEST analysis along with the strategies adopted by major players

Some Points from Table of Content:

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Stem Cell Therapy Market Analysis, Trends, Growth Factor

Chapter 5 Stem Cell Therapy Market Application and Business with Potential Analysis

Chapter 6 Global Stem Cell Therapy Market Segment, Type, Application

Chapter 7 Global Stem Cell Therapy Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Stem Cell Therapy Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Make an Inquiry of the Stem Cell Therapy Market Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=bh

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the rest here:
Stem Cell Therapy Market Growth Analysis 2020 By Industry Top Manufacturers, Business Opportunities, Industry Growth, Size, Gross Margin, Regional...

Stem Cell Media Market 2020 Industry Analysis and Trends Forecast to 2026 Thermo Fisher, CellGenix, Lonza, STEMCELL Technologies, Corning – The Think…

Methodical research based conclusions drawn in the report presented by Orbis Pharma Reports on Stem Cell Media market is designed and articulated on the basis of thorough analytical study, extensive research endeavors as well as minute detail compilation, prolonged observation that eventually result in optimal comprehension as well as systematic decoding of the Stem Cell Media market. A thorough methodical research synopsis on the aforementioned Stem Cell Media market based on Orbis Pharma Reports expert analysts suggest that this well-orchestrated documentation is an output of high end research initiatives and an amalgamation and flawless evaluation of a series of elements, events, triggers that are obtained by various tools that gradually shape the growth curve in global Stem Cell Media market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: https://www.orbispharmareports.com/sample-request/46734

This dedicated, well-planned report mindfully crafted by Orbis Pharma Reports is based on various market analytical tools such as PESTEL and SWOT analysis that thoroughly instigate strength and confidence in the potential marketing strategies that reciprocate and direct the Stem Cell Media market towards optimistic growth in global Stem Cell Media market.

Major Company Profiles operating in the Stem Cell Media Market:

Thermo Fisher CellGenix Lonza STEMCELL Technologies Corning Merck Millipore PromoCell Miltenyi Biotec GE Healthcare Takara HiMedia

By the product type, the market is primarily split into:

Pluripotent Stem Cell Culture Hematopoietic Stem Cell Culture Mesenchymal Stem Cell Culture Others

By the application, this report covers the following segments:

Scientific Research Industrial Production

A thorough review of drivers, restraints and challenges have been considered in detail to derive logical conclusions concerning future growth scope in the aforementioned market has also been pinned in this section of the report presented by Orbis Pharma Reports pertaining to Stem Cell Media market.

The current status of the Stem Cell Media market is thoroughly influenced by the current pandemic crisis of COVID-19 outbreak that has hit the market adversely, whereby several prominent economies are undergoing a massive transformation after having witnessed a sharp plummeting impact on growth prognosis in the past few months.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.orbispharmareports.com/enquiry-before-buying/46734

This ready-to-refer market presentation elaborating on various touchpoints about the Stem Cell Media market is accurately designed and distributed by Orbis Pharma Reports highlighting prevalent market states and conditions, all in place to suit the best interests of the readers, such that enabling them to abandon previous notions and orchestrate new business deals, based on existing market status to ensure vigorous growth in Stem Cell Media market.

As the report makes judicious advances based on aforementioned inferences about Stem Cell Media market presented by Orbis Pharma Reports, backing upon best in industry practices, it carefully unfurls ample light on elements such as current, historic, as well as future growth rendering prospects characteristic to the market growth trends limited to Stem Cell Media market.

The report presented by Orbis Pharma also involves crucial evidence based references on various market circumstances as well as protuberant segments encompassing type and applications that increase high end growth and revenue generation in the global Stem Cell Media market in the forthcoming years.

Access Complete Report @ https://www.orbispharmareports.com/covid-19-impact-on-2020-2026-global-and-regional-stem-cell-media-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version/

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A. +1 (972)-362-8199 [emailprotected]

Continued here:
Stem Cell Media Market 2020 Industry Analysis and Trends Forecast to 2026 Thermo Fisher, CellGenix, Lonza, STEMCELL Technologies, Corning - The Think...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Projected to Grow Massively in Near Future – The Daily Philadelphian

The Autologous Stem Cell and Non-Stem Cell Based Therapies Market report gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take market research report service which has become enough vital in todays market place.

The report represents a professional and all-inclusive study of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis. This market report explains an array of aspects of the market analysis which todays businesses call for. It has become the requisite of this rapidly changing marketplace to take up such Autologous Stem Cell and Non-Stem Cell Based Therapies Market report that makes aware of the market conditions around.

Get Free Sample PDF (including COVID19 Impact Analysis) of Autologous Stem Cell and Non-Stem Cell Based Therapies Market[emailprotected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and Insights:

Europe autologous stem cell and non-stem cell based therapies market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed growing awareness of the therapeutic potential of stem cells in effective disease management and increased public-private investment in the development of stem cell therapies.

This report examines all the key factors influencing the growth of Autologous Stem Cell and Non-Stem Cell Based Therapies market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Autologous Stem Cell and Non-Stem Cell Based Therapies market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Prominent Key Players Covered in the report:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics:

The Autologous Stem Cell and Non-Stem Cell Based Therapies report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Major Regions as Follows:

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

How Does This Market Insights Help?

Key Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast

Reasons to Purchase this Report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries includes Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail: [emailprotected]

Link:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Projected to Grow Massively in Near Future - The Daily Philadelphian

Global Live Cell Imaging Markets, 2020-2025 – Growing Adoption of High-Content Screening Techniques in Drug Discovery – Yahoo Finance UK

Bloomberg

(Bloomberg) -- Stocks slumped and Treasuries rallied as a resurgence in coronavirus cases added to concern about tougher restrictions that could slow down the economic recovery without further stimulus.The S&P 500 sank as much as 1.4% as New York City -- the early epicenter of the pandemic in the U.S. -- prepared for the possibility of closing its schools while Chicago issued an advisory urging residents to avoid leaving home except for work and other essential activities. The Trump administration is stepping back from talks on a government relief package and leaving it up to Congress to revive negotiations with House Speaker Nancy Pelosi, according to people familiar with the situation. Majority Leader Mitch McConnell took the first step for the Senate to confirm Judy Shelton as soon as the coming week to the Federal Reserve board, one of President Donald Trumps outstanding two nominations.All major groups in the American equity benchmark retreated, led by declines in energy producers and banks. While the Nasdaq 100 erased earlier gains, it outperformed other benchmarks on bets that tech companies flush with cash will remain as a safety trade. The Russell 2000 index of smaller companies sank.Read: Raging Virus, Fresh Restrictions Bite Budding Rotation TradeThree of the worlds top central bankers warned Thursday that the prospect of a Covid-19 vaccine isnt enough to put an end to the economic challenges created by the pandemic. Coronavirus infections and hospitalizations are rising in 49 U.S. states, compared with a week ago, according to Covid Tracking Project data. Deaths, a lagging indicator, are climbing in 35. And the velocity at which records are being shattered suggests any decline may yet be far off. The U.S. recorded 152,255 new infections on Wednesday as the virus spreads across the nation, with fatalities reaching their highest point since May.The blame seems to be going to the increased cases of Covid-19 in the U.S. and around the world, and the proposed lockdowns that are going along with it, said Matt Maley, chief market strategist at Miller Tabak + Co, referring to the drop in equities. This makes total sense, but we also need to recognize that this is not new news at all. Therefore, we think the real reason for the weakness is the simple fact that the stock market had become overbought on a very short-term basis.JPMorgan Asset Management is cutting its projections for cross-asset returns over the next decade and signaling more pain for 60/40 allocations that have long formed the bedrock of traditional portfolios. Strategists at the firm reduced their estimate for global equities by 1.4 percentage point to 5.1% a year in the next decade, citing elevated valuations in U.S. large caps. They forecast negative inflation-adjusted returns across almost all sovereign bonds over the next 10 to 15 years, with yields remaining low even after rates normalize.U.S. stocks are likely to fall short in their push to break a dot-com era record, according to Chris Kimble, chief executive officer of Kimble Charting Solutions. Kimble analyzed the ratio between the Nasdaq 100 and the Dow Jones Industrial Average in a blog post this week. The ratio climbed as much as 40% this year through Sept. 1, when it reached the highest level since March 2000, according to data compiled by Bloomberg. On Monday and Tuesday, the ratio fell by a combined 7.4%. The two-day drop was the steepest since May 2001.These are some of the main moves in markets:StocksThe S&P 500 Index dipped 1.3% as of 2:47 p.m. New York time.The Stoxx Europe 600 Index decreased 0.9%.The MSCI Asia Pacific Index rose 0.3%.CurrenciesThe Bloomberg Dollar Spot Index climbed 0.1%.The euro climbed 0.2% to $1.1798.The Japanese yen strengthened 0.2% to 105.20 per dollar.BondsThe yield on 10-year Treasuries fell eight basis points to 0.89%.Germanys 10-year yield sank three basis points to -0.54%.Britains 10-year yield slid seven basis points to 0.348%.CommoditiesThe Bloomberg Commodity Index was little changed.West Texas Intermediate crude increased 1% to $41.88 a barrel.Gold rose 0.5% to $1,875.85 an ounce.(An earlier version of the wrap corrected spelling of strategist name in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2020 Bloomberg L.P.

See original here:
Global Live Cell Imaging Markets, 2020-2025 - Growing Adoption of High-Content Screening Techniques in Drug Discovery - Yahoo Finance UK

GLOBAL STEM CELL MARKET FORECAST 2021-2028 – GlobeNewswire

November 11, 2020 09:24 ET | Source: ReportLinker

New York, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL STEM CELL MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p05478235/?utm_source=GNW

MARKET INSIGHTS Stem cells possess remarkable potential, in terms of promoting wound repaid in a paracrine manner and cutaneous tissue regeneration.As mesenchymal stem cells, numerous cell types, embryonic stem cells, epithelial stem cells, resident tissue stem cells, hematopoietic stem cells, and adipose-derived stem cells are presently under extensive investigation.

As a result, this is likely to contribute to the significant growth of the stem cell market. Umbilical cord stem cells as a non-invasive and efficacious alternative source of hematopoietic stem cells are gaining added awareness and prevalence.They are primarily utilized for treating a varied range of blood-, metabolic-, bone-, and immune system-related disorders and diseases.

Moreover, the knowledge regarding the importance of the umbilical cord, as well as its applications, especially across developed markets, is steadily increasing.

REGIONAL INSIGHTS The global stem cell market growth analysis includes the Asia Pacific, Europe, North America, and the rest of the world.The Asia Pacific observes an increased incidence of chronic diseases, such as cancer, in addition to growing medical tourism in developing nations like India and China, as well as improved economic stability.

As a result, the region is anticipated to be the fastest-growing market for stem cells.

COMPETITIVE INSIGHTS Since stem cells play a crucial role in toxicology studies and drug discovery, the intensity towards optimizing the technical strength for stem cells is continually growing.This factor is also crucial in bolstering the growth of the companies operating in the market.

Hence, the degree of competitive rivalry is anticipated to increase further, and remain high, over the forecast period. The markets key players include, Corning Inc, Becton, Dickinson and Company (BD), GE Healthcare, Smith & Nephew PLC, Qiagen NV, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porters Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned 1. ALLCELLS LLC 2. BECTON, DICKINSON AND COMPANY (BD) 3. CORNING INC 4. CYTORI THERAPEUTICS 5. GE HEALTHCARE 6. INTERNATIONAL STEM CELL CORP 7. MERCK KGAA (SIGMA ALDRICH) 8. MILTENYI BIOTEC 9. PLURISTEM THERAPEUTICS INC 10. QIAGEN NV 11. SMITH & NEPHEW PLC 12. STEMCELL TECHNOLOGIES 13. STRYKER CORPORATION 14. TAKARA HOLDINGS INC 15. THERMO FISHER SCIENTIFIC INC Read the full report: https://www.reportlinker.com/p05478235/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continue reading here:
GLOBAL STEM CELL MARKET FORECAST 2021-2028 - GlobeNewswire